Prof. Dr. med. Arndt Hartmann

Lehrstuhl für Allgemeine Pathologie und Pathologische Anatomie

CD8+ Cytotoxic Immune Infiltrate in Non-Muscle Invasive Bladder Cancer: A Standardized Methodology to Study Association with Clinico-Pathological Features and Prognosis (2019) Masson-Lecomte A, Maille P, Pineda S, Soyeux P, Sagrera A, Rava M, Lopez De Maturana E, et al. Journal article Long-Term Experience of Chemoradiotherapy Combined with Deep Regional Hyperthermia for Organ Preservation in High-Risk Bladder Cancer (Ta, Tis, T1, T2) (2019) Merten R, Ott O, Haderlein M, Bertz S, Hartmann A, Wullich B, Keck B, et al. Journal article Loss of enhancer of zeste homologue 2 (EZH2) at tumor invasion front is correlated with higher aggressiveness in colorectal cancer cells (2019) Böhm J, Muenzner JK, Caliskan A, Ndreshkjana B, Erlenbach-Wünsch K, Merkel S, Croner R, et al. Journal article Multicentric analytical comparability study of programmed death-ligand 1 expression on tumor-infiltrating immune cells and tumor cells in urothelial bladder cancer using four clinically developed immunohistochemistry assays (2019) Schwamborn K, Ammann JU, Knüchel R, Hartmann A, Baretton G, Lasitschka F, Schirmacher P, et al. Journal article Gpr126 (Adgrg6) is expressed in cell types known to be exposed to mechanical stimuli (2019) Musa G, Cazorla-Vázquez S, van Amerongen MJ, Stemmler M, Eckstein M, Hartmann A, Braun T, et al. Journal article Prognostic effect of Ki-67 in common clinical subgroups of patients with HER2-negative, hormone receptor-positive early breast cancer (2019) Fasching P, Gaß P, Häberle L, Volz B, Hein A, Hack C, Lux MP, et al. Journal article Pathology and molecular pathology of renal cell cancer Pathologie und Molekularpathologie des Nierenzellkarzinoms (2019) Erlmeier F, Agaimy A, Hartmann A, Stöhr CG Journal article, Review article Leukocytosis and neutrophilia as independent prognostic immunological biomarkers for clinical outcome in the CAO/ARO/AIO-04 randomized phase 3 rectal cancer trial (2019) Diefenhardt M, Hofheinz RD, Martin D, Beißbarth T, Arnold D, Hartmann A, von der Grün J, et al. Journal article Performance of the Food and Drug Administration/EMA-approved programmed cell death ligand-1 assays in urothelial carcinoma with emphasis on therapy stratification for first-line use of atezolizumab and pembrolizumab (2019) Eckstein M, Erben P, Kriegmair MC, Worst TS, Weiss CA, Wirtz RM, Wach S, et al. Journal article FOXM1 overexpression is associated with adverse outcome and predicts response to intravesical instillation therapy in stage pT1 non-muscle-invasive bladder cancer (2019) Breyer J, Wirtz RM, Erben P, Rinaldetti S, Worst TS, Stoehr R, Eckstein M, et al. Journal article